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Abstract
Background
Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or
mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different
Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the high-
est incidences of the disease in South America and the diagnosis is done by parasitological
techniques. Our aim was to describe the clinical and immunological characteristics of CL
and MCL patients attending the leishmaniasis reference center in Cochabamba, Bolivia, in
order to gain updated clinical and epidemiological information, to evaluate the diagnostic
methods used and to identify biomarkers related to clinical disease and its evolution.
Methodology/Principal findings
The study was conducted from September 2014 to November 2015 and 135 patients with
lesions compatible with CL or MCL were included. Epidemiological and clinical data were
collected using a semi-structured questionnaire. Two parasitological diagnostic methods
were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained
from participants were used to measure the concentrations of different cytokines. 59.2%
(80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of
the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8%
were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum
concentrations in the MCL clinical presentation compared to CL cases and no-cases. None
of the cytokines presented different concentrations between primo-infections and secondary
infections due to treatment failure.
Conclusions/Significance
In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leish-
maniasis because of its high specificity, whereas the sensitivity varies over a wide range
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leading to loss of cases. Until more accurate tools are implemented, all patients should be
tested by both smears and culture of lesion aspirates to minimize the risk of false negatives.
Our results showed higher concentrations of several cytokines in MCL compared to CL, but
no differences were observed between CL and no-cases. In addition, none of the cytokines
differed between primary and secondary infections. These results highlight the need of fur-
ther research to identify biomarkers of susceptibility and disease progression, in addition to
looking at the local cellular immune responses in the lesions.
Author summary
Tegumentary leishmaniasis is a parasitic disease caused by different Leishmania species
and transmitted by phlebotomine sand flies. The disease is distributed worldwide and it
can present a cutaneous or mucocutaneous clinical form. The clinical outcomes of the dis-
ease depend on factors inherent to the parasite, the vector and the host. Bolivia has one of
the highest incidences of the disease in South America, where the diagnosis is mainly
done by parasitological techniques. The present study was conducted from September
2014 to November 2015 with 135 patients attending the leishmaniasis reference centre in
Cochabamba (Bolivia). We aimed to describe the clinical, epidemiological and immuno-
logical characteristics of leishmaniasis patients to gain knowledge on tegumentary leish-
maniasis and evaluate the suitability of the diagnostic methods used. In South America,
Giemsa-stained smears and the culture of lesion aspirates remain the reference standards
in diagnosis because of their high specificity, however the sensitivity varies over a wide
range resulting in some loss of case detection. Until more accurate tools are implemented,
all patients should be screened by both tests to minimize the risk of false negatives. Addi-
tionally, for better disease management, identification of biomarkers of susceptibility and
disease progression would be desirable.
Introduction
Tegumentary leishmaniasis (TL) has two different clinical presentations: ulcerative skin lesions
(cutaneous leishmaniasis [CL]) or a destructive mucosal inflammation (mucocutaneous leish-
maniasis [MCL]) that affects oral-nasal-pharyngeal cavities. MCL usually appears after a CL
episode but both clinical forms can present together [1]. The clinical outcomes of the disease
depend on factors inherent to the parasite, the vector, and the host. CL patients should be diag-
nosed and treated even if CL lesions may self-resolve in up to 70–80% of cases, as they can
cause a high degree of morbidity, social stigmatization, and in some cases evolve to MCL [1].
Bolivia is one of the endemic countries with the highest incidence of CL and MCL in South
America [1,2]. The Leishmania (Viannia) braziliensis species, transmitted by phlebotomine
sand flies, is the predominant etiological agent causing CL in Bolivia (85% of cases) [1,2,3]. CL
is endemic to 70% of Bolivia, with 54.7 cases per 100,000 individuals in 2018 [1,4,5,6].
In Bolivia, diagnosis of leishmaniasis is done by Parasitological Direct Exam (PDE) and in a
few cases, by parasite culture method (CM). Patients cover the cost of both diagnostics. TL
treatment is free of charge but it is only provided when the case has been confirmed. In Bolivia,
first-line TL therapy is meglumine antimoniate (Glucantime), administered by intravenous or
intramuscular injection, depending on the clinical form of the disease (CL and MCL, respec-
tively), at a dosage of 20 mg SbV/kg/day over a period of 20 to 30 days. Second-line treatment
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is amphotericin B deoxycholate (Fungizone) at a dosage of 0.5-1mg/kg/day administered
intravenously for 30 to 45 days requiring a prolonged hospitalization [4,7,8]. However, therapy
failures and variable efficacy of these drugs have been reported [1,7,9].
This study aimed to describe the clinical and immunological characteristics of CL and MCL
patients attending the leishmaniasis reference center in Cochabamba. The study is relevant to
have a realistic description of the population affected by TL in this low-income country area,
and to identify potential problems associated with disease management, such as gaps in the
diagnostic tools currently used. The study also assessed the usefulness of cytokines as biomark-
ers of clinical presentation and treatment failure, and highlights the need for further research
on biomarkers of susceptibility and disease progression in leishmaniasis.
Materials and methods
Ethics statement
The study was approved by the Ethics Committees of the Hospital Clı́nic de Barcelona, Spain
(HCB/2014/0582); CEADES Salud y Medio Ambiente and the Facultad de Medicina UMSS in
Bolivia.
All suspected cases of leishmaniasis provided written informed consent (parents or guard-
ians in case of patients were under 18 years old) before enrolling in the study. All leishmaniasis
suspects attending LABIMED during the study period, including those not enrolled in the
study, were diagnosed for free. CL and MCL cases were referred for treatment.
Study population, data and sample collection
The study was conducted in patients attending the Institute of Biomedical Research,
IIBISMED, and Laboratorios de Investigación Biomédica (LABIMED), from the Faculty of
Medicine of the Universidad Mayor de San Simón (UMSS) in Cochabamba city (Bolivia). Sus-
pects of leishmaniasis are referred to the IIBISMED from other health centres for diagnosis
and treatment.
Patients with lesions compatibles with CL or MCL attending the LABIMED from Septem-
ber 2014 to November 2015 were invited to participate in the study. Subjects from both sexes
and all ages were recruited. After obtaining written informed consent, data on the patients’
demographic, epidemiological and clinical characteristics (number, location and lesion type,
time of evolution, previous drug treatment, duration, and outcome) were collected using a
semi-structured questionnaire (S1 Fig). Smears and aspirates of active lesions were obtained to
diagnose CL and MCL cases. More than one sample was collected per patient if multiple
lesions were present. Blood samples were also obtained by venipuncture.
Diagnostic methods
The diagnostic methods used were: i) microscopic examination of lesion smears obtained by
scrape and stained with Giemsa for the visualization of amastigotes (PDE) and ii) culture of
lesion aspirates from areas of apparent parasitic activity in TSTB (Torrico-Solano-Torrico-Ber-
múdez) biphasic medium (CM) [10]. Cultures were maintained for four weeks and considered
either positive or negative if parasite growth was detected or not and considered contaminated
if non-specific microorganisms were also present. PDE and CM were performed on samples
from three different areas of the same lesion for all the patients who participated in the study.
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Definitions
Based on the clinical and epidemiological data and the results of the diagnostic tests, the fol-
lowing groups of patients were defined.
Clinical forms. Individuals who were positive by microscopy and/or culture were consid-
ered leishmaniasis-confirmed patients. Patients negative by microscopy and culture were con-
sidered no-cases. Patients presenting only cutaneous lesions in any area of the body were
classified as CL, and those with mucosal lesions in mouth and/or nostrils, or concomitant cuta-
neous and mucosal lesions, were classified as MCL.
Primo and secondary infections. CL patients who had no previous history of leishmania-
sis were defined as primo-infection (first episode). MCL patients with no history of CL or visi-
ble scars were considered to have primary lesions [11]. The rest were considered secondary
infections (second episode).
Clinical cure and treatment failure. Clinical cure was defined as complete wound closure
and re-epithelization without inflammation or filtration [12].
We used historical clinical data to identify patients who had a relapse due to treatment fail-
ure. CL and MCL patients who had previously received a complete anti-leishmanial treatment
in the past but were not cured, regardless of its duration, were considered treatment failures.
Those patients presented an absent or incomplete scarring of lesion(s) and/or a persistence of
inflammation around the initial lesion, a clinical regression of a healed lesion or the presence
of new mucosal lesion(s) [1,7,12,13]. For those cases with cutaneous lesions to be considered
treatment failures, the previous treatment had to be directed to the same lesion(s) identified
during our study.
Cytokine, chemokine and growth factor multiplex bead array assay
The Cytokine Human Magnetic 30-Plex Panel from Life Technologies was used to measure
the concentrations (pg/mL) of the following cytokines, chemokines and growth factors in sera:
epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulat-
ing factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte
growth factor (HGF), vascular endothelial growth factor (VEGF), tumor necrosis factor
(TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), mono-
cyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage
inflammatory protein (MIP)-1α, MIP-1β, regulated on activation normal T cell expressed and
secreted (RANTES) and eotaxin.
Twenty five μL of sera were tested by applying a modification to the manufacturer’s proto-
col by using half the volume of all reagents including the standards. This modification was pre-
viously tested and showed no difference in assay performance compared to the original
protocol and has been used in prior studies [14,15]. Each plate included 16 serial dilutions
(2-fold) of a standard sample with known concentrations of each analyte, two blanks and three
positive controls of high, medium and low concentrations in duplicates, prepared from the
standard for quality control purposes. Samples were acquired on a Luminex 100/200 instru-
ment and analyzed with xPONENT software 3.1. Concentrations of analytes were obtained by
interpolating the median fluorescent intensity (MFI) (after blank MFI subtraction) to a
5-parameter logistic regression curve calculated by xPONENT. Values below the lower limit of
detection (mean of blanks + 2 standard deviations) were assigned half the expected concentra-
tion at the lower limit of quantification, and values above the upper limit of quantification
were assigned twice the expected concentration at the upper limit of quantification.
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Statistical analysis
Clinical and epidemiological variables were all categorical and included: age, sex, occupation,
clinical status, probable place of infection, episode of the disease, type and location of lesion,
and questions related to treatment (previous treatments, drug used, dosage and resolution),
among others. Differences in sex, age, number of episodes, characteristics of lesions, and char-
acteristics of previous treatments between clinical forms, were assessed by Pearson’s Chi-
square test at the significance level α = 0.05. The number of patients identified by both diag-
nostic techniques (PDE and CM) was estimated. The agreement between the diagnostic meth-
ods was evaluated using the Cohen’s kappa coefficient (K) calculated after excluding those
cultures that were contaminated. Calculations were performed using the function epi.kappa
from the epiR library in R version 3.5.2 [16].
Cytokine, chemokine and growth factor concentrations were tested for normality to inform
the appropriate statistical analysis, showing a non-normal distribution. Differences in analyte
concentrations between CL, MCL and no-cases, and between primo-infections and treatment
failures (shown as box plots), were compared through the Kruskal-Wallis Chi-squared test
adjusting for multiple comparisons by the Bonferroni correction. The effect of the clinical mani-
festation (CL or MCL) on analyte concentrations was assessed through univariable and multi-
variable linear regression models. Those analytes significant in the univariable models were
included in a stepwise backward multiple regression selection at α = 0.05. The final selected
model was adjusted by age. IBM SPSS Statistics version 24.0.0 (IBM Corp. Released 2016. IBM
SPSS Statistics for Windows, Version 24.0.0 Armonk, NY: IBM Corp.) was used to conduct the
statistical analyses related to the cytokine, chemokine, and growth factor concentrations.
Results
From the 141 suspected leishmaniasis patients who reported to IIBISMED during the study
period, 135 (96%) provided informed consent and were included in the study. From those, 78%
(105/135) and 22% (30/135) were men and women, respectively, from one to 87 years old (�10:
6%; [11–20]: 13%; [21–40]: 47%; [41–60]: 21%;>60: 13%). Eighty (59%) patients were leish-
maniasis-confirmed cases. Excluding the patients with CM contamination (n = 5) we estimated
that only 60% of the cases (45/75; 33 CL and 12 MCL cases) would have been diagnosed by PDE
alone, and 90.6% (68/75; 51 CL and 17 MCL cases) if only CM was conducted. Thirty-eight out
of 75 cases (50.6%) were positive for both PDE and CM (28 CL and 10 MCL cases), showing a
moderate agreement between both diagnostic techniques (K = 0.43; 95% CI: 0.29–0.58).
The prevalence (71.3% CL and 28.7% MCL) and demographic characteristics of leishmaniasis
confirmed cases are shown in Table 1. Among the MCL cases, 19 presented a scar from an old
cutaneous lesion and 4 presented active concomitant cutaneous and mucosal lesions. The major-
ity of leishmaniasis cases were found in men (83.8%), but taking into account the relationship
between the number of confirmed and suspected cases for each sex, no statistical difference was
observed (p = 0.4) (men: 67 confirmed cases/105 suspected cases (p = 0.6): women: 13 confirmed
cases/30 suspected cases (p = 0.4)). The age range most affected was between 21–40 years old
(58.8%; p = 0.004) with a population median age being 32.5 years old. All patients� 20 years old
presented a CL form. Forty-three cases (53.8%) were primo-infections, and two MCL cases with-
out history of cutaneous lesions were classified as primary lesions (2.4%) (Table 1).
The location, number, and type of lesions, as well as time of evolution are shown in Table 2.
Among CL cases, infected ulcerative lesions were the most common (57.9%). Single lesions
were the most frequent (61.4%) (Median: 1; Maximum number of lesions: 8), predominantly
in lower members (43.9%) and with less than 6 months of evolution (82.5%). MCL patients
presented mainly mucosal inflammation.
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Information about the previous treatment in patients presenting a second episode (same
lesion or other lesions in different locations) is summarized in Table 3. Fourteen patients were
considered as treatment failure (considering those who had received a complete treatment):
including ten patients with CL and four patients with MCL. Glucantime (meglumine anti-
moniate) was the most frequently used drug (85%), followed by amphotericine B (5%). No
information on the treatment and its duration was obtained for the rest of patients (10%). The
large majority of patients receiving a second treatment completed it in the past (14/20; 70%)
and, from those, 42.9% (n = 6) showed complete recovery for the past leishmaniasis episode.
One primo-infection patient died during the treatment after an apparent recovery, however
the cause of death was not recorded, although he was reported to have severe malnutrition.
Cytokine profiles differ between CL and MCL clinical forms
Higher concentrations of several cytokines were found in the MCL clinical cases compared to
CL cases (Fig 1): the growth factors VEGF (P = 0.008) and HGF (P = 0.018); the chemokines
eotaxin (P = 0.005), MIP-1α (P = 0.025), MIG (P<0.001) and IP-10 (P = 0.006); the pro-
inflammatory cytokine IL-6 (P = 0.003) and the TH2 cytokine IL-13 (P = 0.042). However,
after correcting for multiple comparisons only MIG remained significantly higher (P = 0.006).
Accordingly, higher concentrations of most of these cytokines were associated with the MCL
phenotype in the univariable regression models, however, after the stepwise multiple regres-
sion selection and adjusting by age, only eotaxin and MIG remained significant (Table 4).
Cytokine profiles do not differ between primo and secondary infections
None of the cytokines presented different concentrations between primo-infections and sec-
ondary infections due to treatment failure. Only the growth factor EGF showed a higher trend
Table 1. Patient characteristics by clinical manifestation of leishmaniasis disease attending the IIBISMED Service
in Cochabamba Department between 2014 and 2015.
CL MCL TOTAL
No. (%) patients No. (%) patients No. (%) patients
Patients 57 (71.3) 23 (28.7) 80 (100)
Sex�
Male 46 (68.7) 21 (31.3) 67 (83.8)
Female 11 (84.6) 2 (15.4) 13 (16.3)
Age�
Median (SD) 32.5 (16.6)
�10 6 (100) 0 (0) 6 (7.5)
11–20 8 (100) 0 (0) 8 (10)
21–40 33 (70.2) 14 (29.8) 47 (58.8)
41–60 9 (64.3) 5 (35.7) 14 (17.5)
>60 1 (20) 4 (80) 5 (6.3)
Episode
Primo-infection 43 (95.6) 0 (0) 43 (53.8)
Secondary-infection 14 (40) 21 (60) 35 (43.8)
Other�� 0 (0) 2 (4.4) 2 (2.4)
� Association was found between the clinical form and the age range (p = 0.004).
�� Primary lesions: MCL patients with no history of CL or visible scars.
https://doi.org/10.1371/journal.pntd.0009223.t001
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in the secondary infections, but the difference was borderline (P = 0.055), and not statistically
significant after multiple comparisons (P = 1) (S2 Fig).
Discussion
In South America, parasitological diagnosis remains the reference standard in diagnosis of CL
because of its high specificity, whereas the sensitivity varies over a wide range, and is much
lower in MCL cases due to the scarcity of amastigotes [17]. In this study, nearly 60% of the 135
CL and MCL suspects tested by microscopy and culture were confirmed to be leishmaniasis
cases. This result is consistent with the prevalence previously found in the tropic of Cocha-
bamba, where 64% of cutaneous lesions proved to be leishmaniasis, with the rest being from
other etiological origins [18]. However, it must be pointed out that some cases are missed due
to the low sensitivity of the two diagnostic methods [17]. Until more accurate tools are imple-
mented (e.g. PCR) all patients should be screened by both tests to minimize the risk of false
negatives. As found in the current study, by only using PDE which is a more subjective tech-
nique, 40% of the cases would have been missed due to its low sensitivity that ranges from 15
to 70% [19]. On the contrary, by using CM alone, only 9.4% of cases would have been
Table 2. Characteristics of clinical forms of leishmaniasis disease in patients attending the IIBISMED Service in
Cochabamba Department between 2014 and 2015.
CL MCL
No. (%) patients No. (%) patients
Cases 57 (71.3) 23 (28.7)
Type of cutaneous lesion
Ulcerative infected 33 (57.9) 2�� (50)
Ulcerative non infected 19 (33.3) 1�� (25)
Other clinical forms� 5 (8.8) 1�� (25)
Number of cutaneous lesions
1 35 (61.4) 2�� (50)
>1 22 (38.6) 2�� (50)
Location (cutaneous)
Upper member 12 (21.1) 1�� (25)
Lower member 25 (43.9) 0 (0)
Face 13 (22.8) 1�� (25)
Neck 1 (1.8) 0 (0)
Trunk 1 (1.8) 0 (0)





More than one location 8 (34.8)
Time of evolution
� 6 months 47 (82.5) 7 (30.4)
6 months—1 year 5 (8.8) 3 (13)
> 1 year 5 (8.8) 13 (56.5)
CL: Cutaneous leishmaniasis; MCL: Mucocutaneous leishmaniasis.
� Nodular, infiltrative, proliferative and verrucous lesions.
�� Patients with MCL that presented concomitant active cutaneous lesions.
https://doi.org/10.1371/journal.pntd.0009223.t002
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overlooked. Five patients could be diagnosed solely by PDE due to culture contamination
(6.3%), which were mainly MCL cases. In our study, the rate of culture contamination was low
(9/135; 6.7%), and stemmed only from fungal microorganisms. The low frequency of contami-
nation was most likely due to the high concentration of antibiotic in the culture medium, the
proper cleaning of the lesions before sampling and the expertise of the laboratory staff [10].
The over-infection of lesions was frequently due to lack of hygiene and/or the use of domestic
treatments, causing a decrease in the sensitivity of the diagnostic techniques if not solved [20].
In this study, 18% of cases were considered to be treatment failures according to the criteria
described above [1,7,12,13]. Llanos-Cuentas and colleagues found that the risk factors associ-
ated with treatment failure were young age, presence of an additional lesion and infection with
L. braziliensis [12]. Patients not included in the main groups (primo-infection or treatment
failure) had different characteristics and were difficult to identify. The majority did not finish
treatment, and others used different plants or solvents to dry the wound or simply burn it.
Occasionally, the lesion self-resolved leaving a scar, but this is not a guarantee of parasitologi-
cal cure, and MCL could still appear after several years [1,20]. Mucosal lesions required hospi-
talization to be treated and may be fatal in some cases [1].
Since the study only included patients arriving passively to be diagnosed, a considerable
number of undiagnosed might have been missed [1,4,21]. Access barriers to case management
were associated with the absence of diagnostic methods and trained staff in rural areas, their
cost, limited accessibility to health centres (scarce and expensive transport, poor road condi-
tions, long travel distances), and adverse climate conditions [4,10,20,21,22]. The local lan-
guages (Quechua and Aymara) and the stigmatization of the disease also hampers
communication with the patients [4,22].
Locations where patients may have acquired the infection were deduced from interviews,
but in some cases this information was not available. As found in other studies, most infections
Table 3. Information about the previous treatment in the 35 patients presenting a second episode of the disease.
CL MCL TOTAL
No. (%) patients No. (%) patients No. (%) patients
Treatment Before the Current Episode (No = 35)
Previous treatment same lesion 11 (78.6) 2 (9.5) 13 (37.1)
Previous treatment other lesions 2 (14.3) 5 (23.8) 7 (20)
Not treated 1 (7.1) 14 (66.7) 15 (42.9)
If treated, drug used (No = 20)
Glucantime 13 (100) 4 (57.1) 17 (85)
Amphotericine B 0 (0) 1 (14.3) 1 (5)
No information 0 (0) 2 (28.6) 2 (10)
If treated, dosage (No = 20)
Complete 10 (76.9) 4 (57.1) 14 (70)
Not complete 1 (7.7) 2 (28.6) 3 (15)
No information 2 (15.4) 1 (14.3) 3 (15)
If complete treatment for the same lesion, resolution (No = 14)
Complete Recovery 4 (40) 2 (50) 6 (42.9)
Partial recovery 5 (50) 0 (0) 5 (35.7)
No recovery 1 (10) 0 (0) 1 (7.1)
No information 0 (0) 2 (50) 2 (14.3)
CL: Cutaneous leishmaniasis; MCL: Mucocutaneous leishmaniasis.
https://doi.org/10.1371/journal.pntd.0009223.t003
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appeared to be acquired in the tropical region of Chapare province (56%), in the department
of Cochabamba [22,23]. The risk of transmission in this area is the highest in the region, as
shown by entomological studies [24,25,26]. The traditional sylvatic pattern of transmission is
the most prevalent in the area [3,22,23,25], but migrations to endemic areas and leishmaniasis
urbanization are also potential means of infection as seen in other countries [22,27,28]. A large
percentage of our population with therapeutic failure had a history of visiting endemic areas
for only short periods, therefore lacking previous exposure to parasite antigens and sand fly
saliva that confer protective immunity [5].
In the present study, the age range most affected was between 21–40 years old and infec-
tions probably occurred during work activities, with more frequent lesions found in the
exposed areas of the body, mainly lower members [1,22,28,29]. These patients described field
activities as farming, fruit and vegetable agriculture, or coca cultivation. Occasionally, women
and children accompanied men to their job activities [23,29]. However, it is worth noting that
the number of women self-presenting was three times lower (30/135) than men. This may be
related to a genuine lower prevalence among women and/or to differences in access to health
services associated to sex as described before [28,29,30]. In addition, leishmaniasis shows sex-
related differences regarding physiology, immune responses, drug metabolism and progres-
sion of the disease [31].
Cellular immunity is essential for controlling intracellular pathogens like Leishmania, and
of primary importance in the outcome of this infection. In the mouse model of L. major, resis-
tance and susceptibility are determined by functionally distinct T cell subsets [32,33], with a
predominant T helper (Th)1 response leading to the control of the infection, and a Th2
response increasing susceptibility and disease progression [34,35]. However, an exaggerated
Th1 response has been associated with tissue damage [36,37]. Our results showing higher con-
centrations of cytokines in MCL agree with previous studies reporting that lymphocyte
Fig 1. Differences in cytokine concentrations between CL, MCL and no-cases. Box plots representing the median and
interquartile range of each marker concentration (pg/mL). Levels between both groups were compared by the Kruskal-
Wallis Chi-squared test adjusting for multiple comparisons by using the Bonferroni correction (P-values in brackets).
Significant P-values (<0.05) are in bold.
https://doi.org/10.1371/journal.pntd.0009223.g001
Table 4. Univariate and multivariable linear regression models to assess the effect of the MCL clinical manifestation on cytokine concentrations. Linear regression
models to assess the effect of MCL on cytokines concentrations.
Coef. (p-value)





Eotaxin 2.72 (0.004) 2.91 (0.008) 2.37 (0.04)
IP-10 1.18 (0.006)
MIG 1.30 (0.002) 1.28 (0.005) 1.21 (0.007)
IL-6 0.73 (0.012)
Age 0.058 (0.010) 0.03 (0.237)
Sex 0.847 (0.323)
� Those cytokines, chemokines or growth factors significantly higher in MCL in the univariable models were included in the stepwise backward multiple regression
selection, and the cytokines selected were included in the final multivariable model adjusted by age. Significant p-values (<0.05) are in bold.
�� Final multivariate model adjusted by age.
https://doi.org/10.1371/journal.pntd.0009223.t004
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activation, proliferation and cytokine secretion upon stimulation with Leishmania antigens are
higher in MCL compared with CL [37,38], probably related to the severity of tissue destruction
in MCL. Among the analytes increased in MCL, we found mainly growth factors (VEGF and
HGF) and chemokines (eotaxin, IP-10, MIG and MIP-1α), as well as the pro-inflammatory
cytokine IL-6 and the Th2 cytokine IL-13. Higher concentrations of growth factors in MCL
may be related to the more severe and extensive tissue destruction and the need of a more active
tissue repair. VEGF is associated with changes in the vasculature during wound healing, and
has been suggested to be important in the development and resolution of leishmanial lesions
[39]. Similarly, HGF is a potent angiogenic factor having a major role in wound healing, acting
upon epithelial and endothelial cells, and on haemopoietic progenitor cells and T cells [40].
The higher concentration of several chemokines in MCL could also be related to the more
extensive wound healing, as they stimulate the migration of multiple cell types to the wound
site, particularly inflammatory cells [41], and contribute to the regulation of re-epithelializa-
tion, tissue remodelling, and angiogenesis [42]. In addition, chemokines may have antimicro-
bial activity involved in parasite clearance. Eotaxin may chemoattract eosinophils to the
infection site for Leishmania clearance [43]. Similarly, IP-10, MIG and MIP-1α, three Th1-mo-
bilizing chemokines produced by leishmaniasis lesion cells, recruit monocytes, macrophages,
and activated T cells to sites of infection, contributing to wound healing and parasite elimina-
tion [44,45]. Neutrophil derived MIP-1α has also been shown to be essential for the recruit-
ment of dendritic cells to the infection site that will further direct the development of an
adaptive immune response [46].
The higher concentration of IL-6 in MCL agrees with a previous association with severity
in visceral leishmaniasis [47,48]. This detrimental effect of IL-6 has been related to its suppres-
sive effect on TNF production and Th1 responses, and its induction of Th2 responses, which is
suggested to down-regulate macrophage microbicidal activity, facilitating Leishmania prolifer-
ation [47]. Finally, the higher concentration of IL-13 in MCL may have a dual role (mainly
Th2 but also Th1 responses) that is influenced by parasite species and the host’s genetic back-
ground [48,49].
Among all these biomarkers, only eotaxin and MIG showed significantly higher concentra-
tions in MCL versus CL after adjustment, indicating their relevant role in the immune
response against the MCL clinical form. Their contribution in recruiting cells to the infected
tissues may be favoring macrophage activation and parasite clearance; however, excessive pro-
duction of these molecules could potentially lead to uncontrolled inflammation and tissue
destruction [45,50]. Thus, it is difficult to disentangle whether the higher concentrations of
these chemokines in MCL versus CL are a positive response to a more extensive infection, or
are in fact contributing to the more generalized inflammation and tissue damage observed in
MCL cases. The absence of association between the levels of cytokines and primo-infections or
secondary infections suggests similar cellular immune responses among them independently
of the type of infection.
One limitation of the study is that the analyses did not consider the Leishmania species
causing the CL and MCL lesions as those were not identified. However, based on previous
studies in the same area, we would expect that over 85% of the cases were caused by L. brazi-
liensis [2,30]. The intrinsic variability of the circulating Leishmania species influences treat-
ment efficacy, thus it is important to be considered for the control of the disease [2]. In
addition, the related lack of data on resistance to antimonials is also important for disease con-
trol, but its incorporation into the diagnostic routine is not realistic in the Bolivian context.
The study does not include healthy individuals as control group for the comparison of cyto-
kine concentrations with leishmanial cases. We only had sera from patients with lesions com-
patible with leishmaniasis but not confirmed as cases, however some cases may have been
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missed due to the low sensitivity of the current diagnostic methods [17]. Finally, quality and
quantity of inflammatory cells in the lesions may differ between clinical phenotypes and
patients, affecting the local cytokine profiles, and this may not be reflected in the serum cyto-
kine profiles. Future studies should address the local cellular immune response in the lesions
to better understand its association to wound healing and evolution of treatment.
In conclusion, the results of the present study provide additional information on the epide-
miological, clinical and immunological situation of TL in Bolivia. Although parasitological
diagnosis remains the reference standard for leishmaniasis the diagnostic techniques evaluated
in the present study evidence that more accurate tools must be implemented in the future to
avoid false negatives. Also, further studies must be done in a larger number of patients relating
clinical manifestations with species characterization considering that Leishmania species iden-
tification might be helpful for better disease management. Regarding the immunological anal-
ysis these results also highlight that further research would certainly present a further step
towards improving knowledge of potential biomarkers of susceptibility and disease
progression.
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adjusting for multiple comparisons by using the Bonferroni correction (P-values in brackets).
Significant P-values (<0.05) are in bold.
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American tegumentary leishmaniasis in endemic areas in rural Bolivia. Rev Soc Bras Med Trop. 2012;
45(1):30–34. https://doi.org/10.1590/s0037-86822012000100007 PMID: 22370825
29. Sosa-Estani S, Segura EL, Gomez A, Salomón OD, Peralta M, Coutada V, et al. Cutaneous leishmania-
sis in Northern Argentina: identification of risk factors in a case-cohort study of three municipalities in
Salta. Rev Soc Bras Med Trop. 2001; 34(6):511–517. https://doi.org/10.1590/s0037-
86822001000600003 PMID: 11813056
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